Results 121 to 130 of about 2,423,946 (178)

Anti-PLA2R positivity does not exclude malignancy in membranous nephropathy: lessons from the course after tumor treatment. [PDF]

Clin Kidney J
Güllülü Boz SE, Yıldız A.
europepmc   +1 more source

CD38-targeted therapies in kidney disease: evidence maturity, disease-stage dependence, and biomarker-guided retreatment. [PDF]

Front Med (Lausanne)
Feng P, Yu X.
europepmc   +1 more source

The clinical features of anti-CNTN1 antibodies associated autoimmune nodopathies with nephropathy: a case series. [PDF]

Front Neurol
Wan J, Xiong T, Hu J, Liu S, Lin J, Zhao C, Sun C, Xiao H.   +7 more
europepmc   +1 more source

Predicting membranous nephropathy remission: a nomogram based on early dynamic biomarkers. [PDF]

Front Med (Lausanne)
Wang C, Hu C, Zhang M, Li R.
europepmc   +1 more source

WCN26-1770 Treatment Options for Idiopathic Membranous Nephropathy with Seronegative Anti-PLA2R Antibody

Kidney International Reports
Yang Yang, Yi Xiong, Fan Yuan, Fang Zeng, Yu Wang, Ran Zhang, Wenjun Yan, Kaiping Luo, Daijin Ren, Gaosi Xu   +9 more
openaire   +1 more source

Belimumab With Rituximab for the Treatment of Primary Membranous Nephropathy. [PDF]

Kidney Int Rep
Chung SA, Stelzig L, Sherman MA, Gao W, Tosta P, Cooney LA, Adler S, Aslam N, Ayoub I, Bomback AS, Coppock G, Derebail VK, Kamal F, Rizk DV, Tuttle KR, Waldman M, Barry WT, Nachman PH.   +17 more
europepmc   +1 more source

The BAFF/APRIL system in autoimmune nephropathy: from pathogenesis to targeted biologic therapies. [PDF]

Front Med (Lausanne)
Jia Y, Yu Z, Xue Y, Pan G, Jiang X, Zhang F.   +5 more
europepmc   +1 more source

Diagnostic performance and inter-observer reproducibility of glomerular PLA2R immunohistochemistry in primary membranous nephropathy: a multi-laboratory blinded observer study. [PDF]

BMC Nephrol
Tougaard BG, Krag S, Gravesen E, Kristensen ME, Madsen K, Riis LB, Krustrup D, Ivarsen P.   +7 more
europepmc   +1 more source

Contemporary review of primary membranous nephropathy. [PDF]

Front Immunol
Filippone EJ, Farber JL.
europepmc   +1 more source

Efficacy and safety of obinutuzumab in patients with primary membranous nephropathy: a focus on refractory and rituximab-resistant patients. [PDF]

Front Immunol
Gao Q, Yao G, Sun Y, Li X, Li Z, Chen B.
europepmc   +1 more source